Journal for ImmunoTherapy of Cancer (Nov 2023)
629-B Window of opportunity for durvalumab plus metformin trial in head & neck squamous cell carcinoma (HNSCC)
- Madalina Tuluc,
- Jennifer Johnson,
- Derek Mann,
- Ubaldo Martinez-Outschoorn,
- Adam J Luginbuhl,
- Athanassios Argiris,
- Ramez Philips,
- Angela Alnemri,
- Sruti Tekumalla,
- Hushan Yang,
- Alban Linnenbach,
- Diana Menezes,
- Voichita Bar-Ad,
- David Cognetti,
- Ramakrishna Mitra,
- Joseph M Curry
Affiliations
- Madalina Tuluc
- 3Thomas Jefferson University, Philadelphia, PA, USA
- Jennifer Johnson
- 2Thomas Jefferson University, Philadelphia, PA, USA
- Derek Mann
- 2Thomas Jefferson University Hospitals, Philadelphia, PA, USA
- Ubaldo Martinez-Outschoorn
- 2Thomas Jefferson University Hospitals, Philadelphia, PA, USA
- Adam J Luginbuhl
- 2Thomas Jefferson University, Philadelphia, PA, USA
- Athanassios Argiris
- 2Thomas Jefferson University Hospitals, Philadelphia, PA, USA
- Ramez Philips
- 1Vanderbilt University Medical Center, Nasvhille, TN, USA
- Angela Alnemri
- 2Thomas Jefferson University Hospitals, Philadelphia, PA, USA
- Sruti Tekumalla
- 2Thomas Jefferson University Hospitals, Philadelphia, PA, USA
- Hushan Yang
- 2Thomas Jefferson University Hospitals, Philadelphia, PA, USA
- Alban Linnenbach
- 2Thomas Jefferson University Hospitals, Philadelphia, PA, USA
- Diana Menezes
- 2Thomas Jefferson University Hospitals, Philadelphia, PA, USA
- Voichita Bar-Ad
- 2Thomas Jefferson University Hospitals, Philadelphia, PA, USA
- David Cognetti
- 2Thomas Jefferson University Hospitals, Philadelphia, PA, USA
- Ramakrishna Mitra
- 2Thomas Jefferson University Hospitals, Philadelphia, PA, USA
- Joseph M Curry
- 2Thomas Jefferson University Hospitals, Philadelphia, PA, USA
- DOI
- https://doi.org/10.1136/jitc-2023-SITC2023.0629-B
- Journal volume & issue
-
Vol. 11,
no. Suppl 2
Abstract
No abstracts available.
